Claims
- 1. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of the following compounds:
- 2. A pharmaceutical composition of claim 1, wherein the Supragenus A-D are represented by the formulas:
- 3. The compound of claim 1, wherein said polycyclic aliphatic group is selected from the group consisting of adamantyl, bicycloheptyl, camphoryl, bicyclo[2,2,2]octanyl and norbornyl.
- 4. The compound of claim 1, wherein said heteroaryl and said substituted heteroaryl is selected from the group consisting of pyridines, thiazoles, isothiazoles, oxazoles, pyrimidines, pyrazines, furans, thiophenes, isoxazoles, pyrroles, pyridazines, 1,2,3-triazines, 1,2,4-triazines, 1,3,5-triazines, pyrazoles, imidazoles, indoles, quinolines, isoquinolines, benzothiophines, benzofurans, parathiazines, pyrans, chromenes, pyrrolidines, pyrazolidines, imidazolidines, morpholines, thiomorpholines, and the corresponding heterocyclics.
- 5. The pharmaceutical composition of claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction, cell proliferation, and/or inhibition of cytokines or leukocytes.
- 6. The pharmaceutical composition of claim 1, wherein R1 and R2 are independently selected from the group consisting of:
- 7. The pharmaceutical composition of claim 1 comprising a compound selected from the group consisting of compounds S-1 to S-25.
- 8. A pharmaceutical composition for treating or preventing an allergic reaction associated increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of the following compounds:
- 9. The pharmaceutical composition of claim 8 comprising a compound selected from the group consisting of compounds S-4, S-5, S-6, S-7, S-8, S-11, S-13, S-15 and S-16.
- 10. The pharmaceutical composition of claim 9 comprising the compound S-7.
- 11. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of the following compounds:
- 12. The pharmaceutical composition of claim 11 comprising a compound selected from the group consisting of compounds S-17, S-19, S-20, and S-21.
- 13. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of the following compounds:
- 14. The pharmaceutical composition of claim 13 comprising the compound S-24.
- 15. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of the following compounds:
- 16. The pharmaceutical composition of claim 15 comprising the compound S-25.
- 17. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of the following compounds:
- 18. A method for treating or preventing an allergic reaction and/or for inhibiting cytokines or leukocytes in a mammal comprising administering an effective amount of any one or more of the following compounds:
- 19. The method of claim 18 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.
- 20. The method of claim 19, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β2-adrenergic agonist, a long-acting 2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.
- 21. The method of claim 19, wherein said at least one additional ingredient is combined with said compound in a pharmaceutically acceptable diluent and co-administered to the mammal.
- 22. The method of claim 18, wherein said compound is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.
- 23. The method of claim 22, wherein said dose is administered in divided doses at regular periodic intervals.
- 24. The method of claim 23, wherein said regular periodic intervals occur daily.
- 25. A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of any one or more of the following compounds:
- 26. The method of claim 25 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said asthma.
- 27. The method of claim 26, wherein said additional ingredient is selected from the group consisting of a short-acting β2-adrenergic agonist, a long-acting β2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.
- 28. A method for inhibiting cellular proliferation in a mammal comprising administering an amount of any one or more of the following compounds:
- 29. The method of claim 28 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said cellular proliferation.
- 30. The method of claim 29, wherein said at least one additional ingredient is selected from the group consisting of antifungals, antivirals, antibiotics, anti-inflammatories, and anticancer agents.
- 31. The method of claim 29, wherein said at least one additional ingredient is selected from the group consisting of alkylating agent, antimetabolite, DNA cutter, topoisomerase I poison, topoisomerase II poison, DNA binder, and spindle poison.
- 32. The method of claim 29, wherein said at least one additional ingredient is combined with said compound in a pharmaceutically acceptable diluent and co-administered to the mammal.
- 33. The method of claim 28, wherein said compound is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.
- 34. The method of claim 33, wherein said dose is administered in divided doses at regular periodic intervals.
- 35. The method of claim 34, wherein said regular periodic intervals occur daily.
- 36. The method of claim 28 further comprising administering at least one other therapy which is effective in ameliorating at least one symptom associated with cellular hyperproliferation.
- 37. The method of claim 36, wherein said therapy is an anti-cancer therapy.
- 38. The method of claim 36, wherein said therapy is selected from the group consisting of radiation, immunotherapy, gene therapy, and surgery.
- 39. A method of preparing a compound or salt thereof having the formula:
- 40. A method of preparing a compound or salt thereof having the formula:
- 41. A method of preparing a compound or salt thereof having the formula:
- 42. A method of preparing a compound or salt thereof having the formula:
- 43. A method of preparing a compound or salt thereof having the formula:
- 44. A method of preparing a compound or salt thereof having the formula:
- 45. A method of preparing a compound or salt thereof having the formula:
- 46. A method of preparing a compound or salt thereof having the formula:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 60/410,761, filed Sep. 12, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60410761 |
Sep 2002 |
US |